相关实验视频
Updated: May 7, 2025

07:44
A Porcine Model of Acute Autologous Pulmonary Embolism
Published on: September 6, 2024
246
肺栓塞的管理:一个单一中心的经验
1From the University of Kentucky College of Medicine, Lexington.
Southern medical journal
|January 3, 2025
概括
肺栓塞 (PE) 的管理因风险而异. 低风险和中等风险患者通常接受抗凝药,而高风险患者可能需要先进疗法以获得更好的结果.
科学领域:
- 心脏病学 心脏病学
- 肺部医学 肺部医学
- 血管医学 血管医学
背景情况:
- 肺栓塞 (PE) 是心血管死亡的一个重要原因.
- 有效的管理策略对于改善患者的治疗结果至关重要.
- 了解当前的治疗模式对于质量改善举措至关重要.
研究的目的:
- 评估目前急性肺栓塞的临床管理.
- 评估在PE治疗中遵守风险分层指南.
- 在一个学术机构基于PE风险分层来分析结果.
主要方法:
- 从2016年1月到2019年6月,对775名急性PE患者的回顾性图表审查.
- 使用美国心脏协会关于PE风险分层的指导方针.
- 分析了抗凝血策略,先进疗法和住院死亡率.
主要成果:
- 低风险的PE患者 (n=409) 主要接受氨酸/氨酸 (92%) 治疗,死亡率为0.5%.
- 中级风险PE患者 (n=322) 主要接受抗凝药 (99.4%),死亡率为2.5%.
- 高风险PE患者 (n=66) 的死亡率为39%,经常需要先进疗法 (71%).
结论:
- 适当的风险分层对于管理肺栓塞至关重要.
- 抗凝药对低风险和中等风险PE患者有效.
- 患有RV菌株和血液动力学不稳定的高风险PE患者从先进疗法中受益.
相关概念视频
Flail Chest-II
132
Managing flail chest, a condition characterized by a segment of the chest wall moving independently from the rest of the thoracic cage, requires a comprehensive approach. It includes a thorough assessment of the patient's condition, a diagnostic evaluation to determine the extent of the injury, and the implementation of appropriate medical interventions tailored to the individual's needs.
Assessment:
1. Clinical Evaluation:
History:
Assessment:
1. Clinical Evaluation:
History:
132
Pneumothorax-II
104
Pneumothorax is a medical condition defined by the buildup of air in the pleural space between the lungs and the chest wall. This accumulation of air can lead to partial or complete lung collapse, resulting in a range of clinical manifestations. Understanding the clinical presentation and effective management strategies is crucial for healthcare professionals in providing timely and appropriate care to individuals with pneumothorax.
Clinical Manifestations:
Clinical Manifestations:
104
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
97
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
97

